NLS Pharmaceutics Adds to Shareholder Bridge Loans
Ticker: NCEL · Form: 6-K · Filed: May 22, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | May 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1,000,000.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financing, insider-loan, debt
TL;DR
NLS Pharmaceutics adds to its CHF 875K bridge loan from Chairman Hafner & other shareholders.
AI Summary
NLS Pharmaceutics Ltd. filed a Form 6-K on May 22, 2024, reporting an addendum to its Bridge Loan Agreements. These agreements, initially entered into on November 15, 2023, provided an unsecured loan of CHF 875,000.00 to the company from existing shareholders, including Chairman Ronald Hafner and directors Felix Grisard, Jürgen Bauer, and Maria Nayvalt.
Why It Matters
This filing clarifies the terms of existing financing from key insiders, providing transparency on the company's short-term funding sources.
Risk Assessment
Risk Level: low — The filing is an update on existing loan agreements and does not introduce new financial risks.
Key Numbers
- CHF 875,000.00 — Bridge Loan Amount (Aggregate unsecured loan provided by existing shareholders)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Filer of the report
- Ronald Hafner (person) — Company's Chairman of the Board of Directors and a Bridge Lender
- Felix Grisard (person) — Bridge Lender
- Jürgen Bauer (person) — Bridge Lender
- Maria Nayvalt (person) — Bridge Lender
- CHF 875,000.00 (dollar_amount) — Aggregate amount of the unsecured loan
- November 15, 2023 (date) — Date of initial Bridge Loan Agreements
- May 2024 (date) — Reporting period for the Form 6-K
FAQ
What is the purpose of the addendum to the Bridge Loan Agreements?
The filing does not explicitly state the purpose of the addendum, but it is an update to previously reported loan agreements.
Who are the Bridge Lenders mentioned in the filing?
The Bridge Lenders include Ronald Hafner (Chairman of the Board), Felix Grisard, Jürgen Bauer, and Maria Nayvalt.
When were the original Bridge Loan Agreements entered into?
The original Bridge Loan Agreements were entered into on November 15, 2023.
What is the total amount of the unsecured loan provided by the Bridge Lenders?
The aggregate amount of the unsecured loan is CHF 875,000.00.
Is NLS Pharmaceutics Ltd. a US-based company?
No, NLS Pharmaceutics Ltd. is a foreign private issuer based in Zurich, Switzerland, as indicated by its filing of Form 6-K and the requirement to file annual reports under Form 20-F.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-05-22 09:10:56
Key Financial Figures
- $1,000,000.00 — amount of CHF 875,000.00 (approximately $1,000,000.00) , or the Bridge Loan. Pursuant to the
Filing Documents
- ea0206687-6k_nlsphar.htm (6-K) — 12KB
- ea020668701ex99-1_nlsphar.htm (EX-99.1) — 15KB
- 0001213900-24-045730.txt ( ) — 28KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: May 22, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 2